Factors Influencing Genetic Transcription Initiation And Termination

RNA形成部分的研究旨在理解和利用细胞DNA复制过程，HIV复制与这些细胞事件的关系，以及如何将这些信息用于治疗目的。我们正在研究在DNA复制或转录过程中形成的RNA/DNA杂交体的形成和分辨率。核糖核酸酶H是参与去除RNA/DNA杂交体中RNA的重要酶，在病毒RNA基因组转化为DNA的过程中，与细胞中的DNA复制和HIV复制密切相关。细胞的RNA酶H和HIV利用相似的蛋白质结构来切割RNA的酶机制是相同的。利用细胞内的rnase H，正在开发改变特定疾病相关基因水平的药物。调控RNases H的表达可增强药物的疗效。在这些努力中采用了分子遗传学、生物化学和小鼠动物模型。

Research in the Section on Formation of RNA is directed toward understanding and utilization of processes involved in cellular DNA replication, the relationship of HIV replication to these cellular events, and how to use this information for therapeutic purposes. We are examining the formation and resolution of RNA/DNA hybrids formed during DNA replication or transcription. Ribonucleases H are important enzymes participating in removal of the RNA of the RNA/DNA hybrids and are intimately related to DNA replication in cells and in HIV replication, during the conversion of the RNA genome of this virus to DNA. RNases H of cells and HIV share common enzymatic mechanisms of cleavage of RNA utilizing similar protein architectures. Drugs to alter levels of specific disease-related genes are being developed to take advantage of RNases H within the cell. Regulated expression of RNases H could enhance the efficacy of the drugs. Molecular genetic, biochemical, and mouse animal models are employed in these efforts. During transcription, RNA/DNA hybrids can form and are usually cleaved by RNase H. RNase H recognizes and specifically cleaves RNA of hybrids by several contacts to the RNA and interactions with the DNA strand using a two metal ion mechanism as determined in collaboration with Dr. Wei Yang (NIDDK). We now know that the eukaryotic RNases H are more complex than the bacterial enzymes, and that the enzymatic activity of mouse RNase H1 (and presumably other eukaryotic RNases H1) form a complex when binding to an RNA/DNA hybrid that enables the enzyme to be more efficient when degrading certain types of RNA/DNA hybrids. In collaboration with the groups at NCI- Frederick we have been examining inhibitors of RNases H that could prove useful in HIV-AIDS therapy. From our earlier work showing that the mouse RNase H1 is critical for development, we know that it is important to have drugs that specifically target the HIV-AIDS RNase H not the cellular enzyme. Screening of potential drugs now includes use of the human RNase H1 isolated in our laboratory. AGS is a syndrome whose cause has been assigned to mutations in any of the three subunits of human RNase H2. Our work on the homologous enzyme from Saccharomyces cerevisiae was the first describing the three subunit composition of eukaryotic RNases H2. Deletion of any genes encoding the three subunits of RNase H2 in S. cerevisiae does not result in any major phenotype unless the mutant is combined with any of several other gene deletions, a condition known as synthetic lethality. We are currently examining the biochemical properties of human and S. cerevisiae RNase H2, and, in particular, are examining the role of RNase H2 in DNA replication, repair and recombination. The severe neurological disorder (AGS) an because by mutations in genes encoding at least three different proteins including any of the subunits of human RNase H2. Mutations in the gene encoding Trex1 also cause AGS with the Trex1 protein being defective as a result of the mutation. In contrast, we find that most of the mutations in the genes encoding RNase H2 do not alter the activities of the recombinant enzymes. We are currently trying to sort out how these changes result in in vivo phenotypes.